Topadur Pharma

News

8.9.22

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR Pharma AG has been selected among Switzerland's most promising scale-ups in 2022. Huge thanks to everyone of our team, supporters, and partners believing in us along the way!

Please check out the link below.

‍

Download Document Dokument herunterladen https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022 https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022

20.6.22

News

Scientific Publication in Advanced Therapeutics

Dual-Mode Vasodilator M119 Delivery to Hair Follicle via Dissolving Microneedle for Advanced Alopecia Treatment.

27.5.21

News

Innosuisse innovation project starting May 2021

TOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.

6.7.21

Press Release

TOPADUR Pharma AG announces completion of TOP-N53 First-in-Man Study

TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

Scientific Publication in Advanced Therapeutics

Innosuisse innovation project starting May 2021

TOPADUR Pharma AG announces completion of TOP-N53 First-in-Man Study

Investors

About us

Pipeline

Contact